PortfoliosLab logoPortfoliosLab logo
WUXAY vs. TEVA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

WUXAY vs. TEVA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in WuXi AppTec Co. Ltd (WUXAY) and Teva Pharmaceutical Industries Limited (TEVA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, WUXAY achieves a 24.66% return, which is significantly higher than TEVA's 10.32% return.


WUXAY

1D
-2.21%
1M
-10.17%
YTD
24.66%
6M
22.14%
1Y
68.90%
3Y*
26.25%
5Y*
-6.14%
10Y*

TEVA

1D
4.87%
1M
-3.99%
YTD
10.32%
6M
21.19%
1Y
96.52%
3Y*
68.40%
5Y*
27.05%
10Y*
-4.12%
*Multi-year figures are annualized to reflect compound growth (CAGR)

WUXAY vs. TEVA - Yearly Performance Comparison


2026 (YTD)20252024202320222021
WUXAY
WuXi AppTec Co. Ltd
24.66%84.22%-26.59%-0.53%-41.47%-20.12%
TEVA
Teva Pharmaceutical Industries Limited
10.32%41.61%111.11%14.47%13.86%-29.24%

Correlation

The correlation between WUXAY and TEVA is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.15

Correlation (3Y)
Calculated over the trailing 3-year period

0.10

Correlation (5Y)
Calculated over the trailing 5-year period

0.09

Correlation (All Time)
Calculated using the full available price history since Feb 25, 2021

0.08

Fundamentals

Market Cap

WUXAY:

$45.69B

TEVA:

$40.59B

EPS

WUXAY:

$6.98

TEVA:

$1.34

PE Ratio

WUXAY:

2.22

TEVA:

25.74

PEG Ratio

WUXAY:

0.05

TEVA:

0.20

PS Ratio

WUXAY:

0.93

TEVA:

2.32

PB Ratio

WUXAY:

0.54

TEVA:

4.93

Total Revenue (TTM)

WUXAY:

$48.16B

TEVA:

$17.35B

Gross Profit (TTM)

WUXAY:

$23.73B

TEVA:

$9.03B

EBITDA (TTM)

WUXAY:

$25.29B

TEVA:

$3.05B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

WUXAY vs. TEVA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

WUXAY
WUXAY Risk / Return Rank: 7979
Overall Rank
WUXAY Sharpe Ratio Rank: 7979
Sharpe Ratio Rank
WUXAY Sortino Ratio Rank: 7575
Sortino Ratio Rank
WUXAY Omega Ratio Rank: 7676
Omega Ratio Rank
WUXAY Calmar Ratio Rank: 8484
Calmar Ratio Rank
WUXAY Martin Ratio Rank: 8181
Martin Ratio Rank

TEVA
TEVA Risk / Return Rank: 9191
Overall Rank
TEVA Sharpe Ratio Rank: 9292
Sharpe Ratio Rank
TEVA Sortino Ratio Rank: 9393
Sortino Ratio Rank
TEVA Omega Ratio Rank: 9292
Omega Ratio Rank
TEVA Calmar Ratio Rank: 9090
Calmar Ratio Rank
TEVA Martin Ratio Rank: 9090
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

WUXAY vs. TEVA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for WuXi AppTec Co. Ltd (WUXAY) and Teva Pharmaceutical Industries Limited (TEVA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


WUXAYTEVADifference
Sharpe ratioReturn per unit of total volatility

-1.15

Sortino ratioReturn per unit of downside risk

-1.66

Omega ratioGain probability vs. loss probability

1.27

1.47

-0.20

Calmar ratioReturn relative to maximum drawdown

3.29

4.45

-1.17

Martin ratioReturn relative to average drawdown

6.82

12.15

-5.33

WUXAY vs. TEVA - Sharpe Ratio Comparison

The current WUXAY Sharpe Ratio is 1.34, which is lower than the TEVA Sharpe Ratio of 2.49. The chart below compares the historical Sharpe Ratios of WUXAY and TEVA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


WUXAYTEVADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.34

2.49

-1.15

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.09

0.63

-0.72

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.09

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.06

0.32

-0.38

Drawdowns

WUXAY vs. TEVA - Drawdown Comparison

The maximum WUXAY drawdown since its inception was -84.50%, smaller than the maximum TEVA drawdown of -90.89%. Use the drawdown chart below to compare losses from any high point for WUXAY and TEVA.


Loading charts...

Drawdown Indicators


WUXAYTEVADifference

Max Drawdown

Largest peak-to-trough decline

-84.50%

-90.89%

+6.39%

Max Drawdown (1Y)

Largest decline over 1 year

-21.08%

-21.79%

+0.71%

Max Drawdown (3Y)

Largest decline over 3 years

-71.67%

-43.70%

-27.97%

Max Drawdown (5Y)

Largest decline over 5 years

-84.50%

-43.70%

-40.80%

Max Drawdown (10Y)

Largest decline over 10 years

-88.41%

Current Drawdown

Current decline from peak

-27.17%

-49.11%

+21.94%

Average Drawdown

Average peak-to-trough decline

-47.06%

-32.00%

-15.06%

Ulcer Index

Depth and duration of drawdowns from previous peaks

10.14%

7.97%

+2.17%

Volatility

WUXAY vs. TEVA - Volatility Comparison

WuXi AppTec Co. Ltd (WUXAY) has a higher volatility of 12.87% compared to Teva Pharmaceutical Industries Limited (TEVA) at 8.99%. This indicates that WUXAY's price experiences larger fluctuations and is considered to be riskier than TEVA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


WUXAYTEVADifference

Volatility (1M)

Calculated over the trailing 1-month period

12.87%

8.99%

+3.88%

Volatility (6M)

Calculated over the trailing 6-month period

35.34%

23.65%

+11.69%

Volatility (1Y)

Calculated over the trailing 1-year period

51.67%

38.94%

+12.73%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

72.01%

42.95%

+29.06%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

70.80%

47.32%

+23.48%

Dividends

WUXAY vs. TEVA - Dividend Comparison

WUXAY's dividend yield for the trailing twelve months is around 1.80%, while TEVA has not paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
TEVA
Teva Pharmaceutical Industries Limited
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%3.88%3.19%1.77%
WUXAY
WuXi AppTec Co. Ltd
1.80%3.30%1.93%1.24%0.76%0.23%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

WUXAY vs. TEVA - Financials Comparison

This section allows you to compare key financial metrics between WuXi AppTec Co. Ltd and Teva Pharmaceutical Industries Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


4.00B6.00B8.00B10.00B12.00B20222023202420252026
12.44B
3.98B
(WUXAY) Total Revenue
(TEVA) Total Revenue
Values in USD except per share items

WUXAY vs. TEVA - Profitability Comparison

The chart below illustrates the profitability comparison between WuXi AppTec Co. Ltd and Teva Pharmaceutical Industries Limited over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

35.0%40.0%45.0%50.0%55.0%20222023202420252026
50.4%
49.5%
Portfolio components
WUXAY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, WuXi AppTec Co. Ltd reported a gross profit of 6.27B and revenue of 12.44B. Therefore, the gross margin over that period was 50.4%.

TEVA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported a gross profit of 1.97B and revenue of 3.98B. Therefore, the gross margin over that period was 49.5%.

WUXAY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, WuXi AppTec Co. Ltd reported an operating income of 5.61B and revenue of 12.44B, resulting in an operating margin of 45.2%.

TEVA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported an operating income of 652.00M and revenue of 3.98B, resulting in an operating margin of 16.4%.

WUXAY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, WuXi AppTec Co. Ltd reported a net income of 4.65B and revenue of 12.44B, resulting in a net margin of 37.4%.

TEVA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported a net income of 369.00M and revenue of 3.98B, resulting in a net margin of 9.3%.


Frequently Asked Questions


WUXAY and TEVA have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

WUXAY has higher volatility (12.87%) compared to TEVA (8.99%). In terms of maximum drawdown, WUXAY dropped -84.50% vs TEVA's -90.89%.

TEVA currently has the higher Sharpe Ratio (2.49 vs 1.34), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for WUXAY and TEVA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer